Su Jinqiu, Li Zhuang, Wang Jianli, Liu Nairong, Bao Liyi, Du Jiayuan, Li Yan, Yu Yaojie, Wang He
Department of Gynecology, Affiliated Cancer Hospital of Guangxi Medical University, Guangxi Key Laboratory of Early Prevention and Treatment of Regional High-Incidence Tumors, Nanning, 530021, Guangxi, China.
Discov Oncol. 2024 Nov 2;15(1):613. doi: 10.1007/s12672-024-01491-2.
To determine the effects of anti-B cell surface marker CD20 antibody on the occurrence and progression of endometrial cancer to provide insights into clinical treatment in the future.
We performed a two-sample Mendelian randomization analysis (MR) to analyze the causal relationship between EC and immune cell markers. The genome-wide association study (GWAS) data of MS4A1 single nucleotide polymorphism encoding gene of CD20 were collected, and a drug target MR analysis was performed to detect the causal relationship between anti-CD20 antibody and the risk of EC. The risk of follicular lymphoma was used as a positive control, and EC was used as the outcome.
EC exerted an effect on 28 immunophenotypes, predominantly on CD20. CD20 in immunoglobulin D+ CD38- B cells, memory B cells, and unsw memory B cells increased after EC onset. In addition, we detected one immunophenotype that exerted a dangerous effect on EC, i.e., CD3/TD CD4+ (mature stage of the T cell group). Simultaneously, CD20 could be used as both a risk factor and a protective factor for EC (P > 0.05). Anti-CD20 antibodies significantly reduced the risk of follicular lymphoma, including two GWAS pooled datasets. In addition, anti-CD20 antibodies exerted a protective effect on EC in two GWAS pooled datasets (P > 0.05).
Our study confirms the close relationship between CD20 and EC. Anti-CD20 antibodies may exert a protective effect on EC and reduce the risk of EC morbidity, providing a reference for future clinical diagnosis and treatment. However, further clinical verification of our results is warranted.
确定抗B细胞表面标志物CD20抗体对子宫内膜癌发生发展的影响，为未来临床治疗提供思路。
我们进行了两样本孟德尔随机化分析（MR），以分析子宫内膜癌（EC）与免疫细胞标志物之间的因果关系。收集了编码CD20的MS4A1单核苷酸多态性的全基因组关联研究（GWAS）数据，并进行了药物靶点MR分析，以检测抗CD20抗体与EC风险之间的因果关系。将滤泡性淋巴瘤的风险用作阳性对照，将EC用作结局。
EC对28种免疫表型有影响，主要是对CD20。EC发病后，免疫球蛋白D + CD38 - B细胞、记忆B细胞和未转换记忆B细胞中的CD20增加。此外，我们检测到一种对EC有危险影响的免疫表型，即CD3/TD CD4 +（T细胞组的成熟阶段）。同时，CD20可作为EC的危险因素和保护因素（P>0.05）。抗CD20抗体显著降低了滤泡性淋巴瘤的风险，包括两个GWAS汇总数据集。此外，抗CD20抗体在两个GWAS汇总数据集中对EC有保护作用（P>0.05）。
我们的研究证实了CD20与EC之间的密切关系。抗CD20抗体可能对EC有保护作用，并降低EC发病风险，为未来临床诊断和治疗提供参考。然而，我们的结果需要进一步的临床验证。
